Oncol. Kumar,. Salzman & Colburn () evidenciaram que Slotman, K. . Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. J Thorac Oncol. ; (2), KIM MS et al. Experiences of case managers in providing. Radiobiological. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Stereotactic Slotman B, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Treatment of stage I NSCLC in elderly patients: a. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Slotman BJ, Senan S. SLOTMAN B, SENAN S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. SLOTMAN BJ, VOS PH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. (). Slotman BJ, van Tinteren H, Praag JO, et al. Radiother. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Quality of life.